Abstract 1562: Correlative biomarker analysis of the phase II study of prexasertib, a cell cycle checkpoint kinase 1 (CHK1) inhibitor, in BRCA wild-type (BRCAwt), platinum-resistant recurrent, high-grade serous ovarian cancer (PR-HGSOC)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1562
Abstract: Background: High unmet needs exist to develop novel therapeutics and identify biomarkers to predict response in PR-HGSOC. We previously reported clinical activity of CHK1 inhibitor (CHK1i), prexasertib (a.k.a.ACR-368) in heavily pretreated BRCAwt PR-HGSOC (response rate… read more here.
Keywords: cycle; brcawt; analysis; response ... See more keywords